Current Trends in Cardiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Current Trends in Cardiology (2024) Volume 8, Issue 9

Cardio-Oncology: Bridging the Gap Between Cancer and Cardiovascular Health

Salsali Afshin *

Department of Cardiology, Capital Medical University, China.

 

*Corresponding Author:
Salsali Afshin
Department of Cardiology
Capital Medical University
China
E-mail: AfsinSlsali@gmail.com

Received:23-Aug-2024,Manuscript No. AACC-24-148837; Editor assigned:26-Aug-2024,PreQC No. AACC-24-148837(PQ); Reviewed:09-Sep-2024,QC No. AACC-24-148837; Revised:13-Sep-2024, Manuscript No. AACC-24-148837(R); Published:23-Sep-2024,DOI:10.35841/aacc-8.9.323

Citation: Salsali Afshin. Cardio oncology: Bridging the gap between cancer and cardiovascular health. Curr Trend Cardiol. 2024;8(9):323

Visit for more related articles at Current Trends in Cardiology

Abstract

    

Introduction

As cancer treatments advance, the focus on managing their side effects and complications has become increasingly important. Among these, cardiovascular complications stand out as a significant concern for cancer survivors. This emerging field, known as cardio-oncology, examines the intersection of cardiology and oncology, aiming to address the cardiovascular health of cancer patients before, during, and after treatment. With an increasing number of cancer survivors—over 18 million in the United States alone—the need for specialized care in cardio-oncology is more pressing than ever.The relationship between cancer and cardiovascular disease is complex. Certain cancer treatments, including chemotherapy and radiation, can lead to various cardiovascular problems such as heart failure, arrhythmias, and coronary artery disease. The mechanisms underlying these complications are multifaceted, often involving direct toxicity to heart cells, endothelial dysfunction, and inflammatory responses triggered by both cancer and its treatment.Cardio-oncology recognizes that cancer patients are at an elevated risk for developing cardiovascular diseases. Studies indicate that cancer survivors can have a twofold increased risk of cardiovascular events compared to the general population. Consequently, a multidisciplinary approach involving oncologists, cardiologists, and primary care providers is essential for optimizing patient outcomes. [1,2]. Several factors can contribute to an increased risk of cardiovascular disease in cancer patients.Certain chemotherapy drugs, such as anthracyclines (e.g., doxorubicin) and trastuzumab (Herceptin), are associated with cardiotoxicity. They can cause damage to the heart muscle and lead to heart failure.Radiation to the chest area can affect the heart and surrounding structures, increasing the risk of coronary artery disease and heart valve abnormalities.Hormonal treatments, particularly for breast and prostate cancer, can also contribute to cardiovascular risk by influencing metabolic factors and vascular health.Patients with a history of hypertension, diabetes, or dyslipidemia are more susceptible to cardiovascular complications during cancer treatment.Sedentary behavior, poor nutrition, smoking, and excessive alcohol consumption, which are prevalent among cancer patients, further exacerbate cardiovascular risks.To mitigate cardiovascular risks in cancer patients, a proactive and comprehensive approach is necessary. [3,4]. Before initiating cancer treatment, a thorough cardiovascular evaluation should be conducted. This may involve obtaining a detailed medical history, performing physical examinations, and conducting baseline cardiovascular tests such as echocardiograms, electrocardiograms (ECGs), and exercise stress tests.Regular monitoring for cardiovascular complications during cancer therapy is crucial. Oncologists should collaborate with cardiologists to establish a plan for ongoing assessment, especially for patients receiving high-risk treatments. Biomarkers such as troponin and N-terminal pro b-type natriuretic peptide (NT-proBNP) can be valuable in identifying early signs of cardiotoxicity.Addressing modifiable risk factors is key to reducing cardiovascular risks. This includes managing hypertension, diabetes, and dyslipidemia through lifestyle interventions and medication as needed. Encouraging regular physical activity and a heart-healthy diet can also support cardiovascular health.For patients identified as at high risk for cardiotoxicity, cardioprotective medications may be considered. Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers have shown promise in reducing the incidence of heart failure in patients receiving anthracycline therapy.[5,6]. After completing cancer treatment, long-term cardiovascular follow-up is essential. This can include continued monitoring for heart disease, screening for late-onset cardiotoxicity, and counseling on healthy lifestyle choices to promote overall well-being. The establishment of dedicated cardio-oncology clinics has emerged as a vital component of comprehensive cancer care. These specialized centers provide a collaborative environment where oncologists and cardiologists work together to develop individualized treatment plans that prioritize both cancer management and cardiovascular health.In these clinics, patients receive coordinated care that includes risk assessment, monitoring, and tailored interventions. Education about the potential cardiovascular effects of cancer treatments and the importance of lifestyle modifications is also emphasized. By integrating cardio-oncology into routine cancer care, the aim is to enhance survivorship and improve the quality of life for cancer patients.As the field of cardio-oncology continues to evolve, several areas warrant further exploration. [7,8]. Ongoing research is needed to identify specific biomarkers for early detection of cardiotoxicity and to develop new therapeutic strategies that minimize cardiovascular risks.Long-term studies examining the cardiovascular outcomes of cancer survivors are essential to better understand the lasting effects of cancer treatments on heart health.Increasing awareness among healthcare providers, patients, and caregivers about the risks of cardiovascular disease in cancer patients will facilitate earlier detection and intervention.Emphasizing shared decision-making and personalized care plans that consider patients’ unique needs and preferences will enhance the overall patient experience. [9,10].

Conclusion

Cardio-oncology represents a critical intersection of cardiology and oncology, addressing the cardiovascular health of cancer patients. As the number of cancer survivors continues to rise, the importance of integrated care becomes more apparent. By recognizing and managing cardiovascular risks, healthcare providers can enhance the quality of life for cancer survivors, allowing them to thrive beyond their cancer diagnosis. Through continued collaboration and research, the field of cardio-oncology will play an essential role in shaping the future of cancer care.

References

  1. Agarwal R, Weir MR. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. J Hypertens. 2013; 31(8):1692-701.

    2. Indexed at, Google Scholar, Cross ref

  2. Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005; 5:131-40.

    3. Indexed at, Google Scholar, Cross ref

  3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-67. 

    4. Indexed at, Google Scholar, Cross ref

  4. Gupta AK, Poulter NR, Dobson J, et al. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT trial. Am J Hypertens. 2010; 23(9):1023-1030.

    5. Indexed at, Google Scholar, Cross ref

  5. Krause T, Lovibond K, Caulfield M, et al. Guideline Development Group. Management of hypertension: summary of NICE guidance. 2011; 343:d4891.

    6. Indexed at, Google Scholar, Cross ref

  6. Materson BJ. Variability in response to antihypertensive drugs. Am J Med.2007; 120 (4 Suppl 1):S10-20.

    7. Indexed at, Google Scholar, Cross ref

  7. Hwang NS, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv Drug Deliv Rev. 2007;60(2):199-214.

    8. Indexed at, Google Scholar, Cross Ref 

  8. Kain K. The birth of cloning: an interview with John Gurdon. Dis Model Mech.2009;2(1–2):9-10.

    9. Indexed at, Google Scholar, Cross Ref

  9. Larijani B, Esfahani EN, Amini P, et al. Stem cell therapy in treatment of different diseases. Acta Medica Iranica. 2012;50(2):79-96.

    10. Indexed at, Google Scholar

  10. Lim WF, Inoue-Yokoo T, Tan KS, et al. Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. Stem Cell Res Ther. 2013;4(3):71.

    11. Indexed at, Google Scholar, Cross Ref

Get the App